Calliditas Therapeutics AB (publ) (STO: CALTX)

STO: CALTX Revenue

Calliditas Therapeutics AB had revenue of 559.78M SEK in the quarter ending June 30, 2024, with 107.80% growth. This brings the company's revenue in the last twelve months to 1.60B, up 39.27% year-over-year. In the year 2023, Calliditas Therapeutics AB had annual revenue of 1.21B with 50.32% growth.

• Revenue (ttm): 1.60B
• Revenue Growth: +39.27%
• P/S Ratio: 6.97
• Revenue / Employee: 7.21M
• Employees: 217
• Market Cap: 11.24B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	1.21B	404.01M	50.32%
Dec 31, 2022	802.88M	573.53M	250.07%
Dec 31, 2021	229.35M	228.47M	26,141.08%
Dec 31, 2020	874.00K	-183.96M	-99.53%
Dec 31, 2019	184.83M	-	-